Skip to main content

Advertisement

Table 6 Characteristics of the Study Population (mRNA expression study) (n = 55)

From: Selective accumulation of langerhans-type dendritic cells in small airways of patients with COPD

  Never Smokers Current Smokers without COPD Ex-Smokers without COPD COPD Current Smokers COPD Ex-Smokers
n 10 7 10 17 11
Sex ratio (M/F) 3/7 3/4 8/2 14/3 11/0
Age (years) 59.5 (11.2) 53.1 (13.4) 63.6 (7.7) 63.9 (9.5) 69.3 (7.7)
Smoking history (packyear) 0 34.8 (12) * 37.5 (20.6) * 41.2 (16.9) † 56.1 (24.1) *
Years quit smoking N.A. 0.0 9.0 (10.7) † 0.0 ‡ 5.8 (6.0)†Δ
FEV1 (%pred) 97.3 (13) 101.8 (16.7) 112.2 (10.1) 68.3 (13.6)*†‡ 68.8 (14.6)*†‡
FEV1 (L) 2.8 (0.7) 2.9 (0.4) 3.4 (0.7) 2.3 (0.6)‡ 2.1 (0.5)*†‡
FEV1/FVC (%) 77.2 (8.1) 77.2 (4.9) 77.2 (6.1) 56.1 (7.0)*†‡ 55.6 (9.2)*†‡
LABA (Y/N) 0/10 0/7 0/10 6/11 5/6
Inhaled corticosteroids (Y/N) 0 0 0 6/11 5/6
Inhaled corticosteroid dose (μg BDP/24 h) 0 0 0 538.5 (877.1)*†‡ 663.6 (897.0)*†‡
Systemic corticosteroids (Y/N) 0/10 0/7 0/10 3/14 1/10
Systemic corticosteroid dose (mg prednisolon/24 h) 0 0 0 3.1 (10.0) 0.9 (3.0)
  1. Data are expressed as mean (standard deviation);
  2. * p < 0.05 vs never smoker; † p < 0.05 versus current smoker without COPD; ‡ p < 0.05 versus ex-smoker without COPD; Δ p < 0.05 versus COPD current smoker.
  3. FEV1: forced expiratory volume in one second;
  4. FVC: forced vital capacity;
  5. LABA : long acting β 2 agonist; BDP: beclomethasone diproprionate.